-
EP3741861
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3741861
| EP3741861 - SYNNOTCH RECEPTOR-REGULATED EXPRESSION OF IL12 [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 24.11.2023 Database last updated on 15.06.2024 | |
| Former | Request for examination was made Status updated on 23.10.2020 | ||
| Former | The international publication has been made Status updated on 27.07.2019 | Most recent event Tooltip | 24.11.2023 | Application deemed to be withdrawn | published on 27.12.2023 [2023/52] | Applicant(s) | For all designated states CRAGE medical Co., Limited RM12, 20/F, Ho King Comm CTR 2-16 FaYuen ST Mongkok Kowloon Hong Kong / CN | [2022/18] |
| Former [2021/40] | For all designated states CAFA THERAPEUTICS LIMITED 2/3 Exchange Place I.F.S.C. Dublin D01 AE27 / IE | ||
| Former [2020/48] | For all designated states Carsgen Therapeutics Co., Ltd. Building B Yindu Road 388 Xuhui District Shanghai 200231 / CN | ||
| For all designated states Shanghai Cancer Institute No. 25/Ln 2200 Xietu Road. Xuhui District Shanghai 200032 / CN | Inventor(s) | 01 /
LI, Zonghai Building B, No.388 Yindu Road Xuhui District Shanghai 200231 / CN | 02 /
LUO, Hong Building B, No.388 Yindu Road Xuhui District Shanghai 200231 / CN | 03 /
WANG, Huamao Building B, No.388 Yindu Road Xuhui District Shanghai 200231 / CN | [2020/48] | Representative(s) | reuteler & cie SA Chemin de la Vuarpillière 29 1260 Nyon / CH | [2020/48] | Application number, filing date | 19741277.8 | 21.01.2019 | [2020/48] | WO2019CN72497 | Priority number, date | CN20181053219 | 19.01.2018 Original published format: CN201810053219 | [2020/48] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019141270 | Date: | 25.07.2019 | Language: | ZH | [2019/30] | Type: | A1 Application with search report | No.: | EP3741861 | Date: | 25.11.2020 | Language: | EN | [2020/48] | Search report(s) | International search report - published on: | CN | 25.07.2019 | (Supplementary) European search report - dispatched on: | EP | 10.11.2021 | Classification | IPC: | C12N15/85, C12N15/90, A61P35/00, A61K35/17, A61K39/00, C07K14/725, C07K16/30, C12N5/10, C12N15/86 | [2021/49] | CPC: |
C12N15/86 (EP);
A61P35/00 (EP,CN);
C12N15/90 (US);
A61K39/4611 (EP,CN);
A61K39/4613 (EP,CN);
A61K39/4631 (EP,CN);
A61K39/464474 (EP,CN);
C07K14/5434 (EP,CN,US);
C07K14/7051 (EP);
C07K16/30 (CN);
C07K16/303 (EP);
C12N15/85 (EP,CN,US);
C12N5/0636 (EP,CN);
C12N5/0646 (EP,CN);
C12N5/16 (US);
A61K2239/31 (EP,CN);
A61K2239/38 (EP,CN);
C07K2317/622 (EP,US);
C07K2319/00 (EP);
C12N2501/606 (US);
C12N2510/00 (EP,CN,US);
C12N2740/16043 (EP);
C12N2800/107 (US);
C12N2830/002 (EP);
C12N2830/48 (EP)
(-)
|
| Former IPC [2020/48] | C12N15/85, C12N15/90, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/48] | Title | German: | SYNNOTCH-REZEPTOR-REGULIERTE EXPRESSION VON IL12 | [2020/48] | English: | SYNNOTCH RECEPTOR-REGULATED EXPRESSION OF IL12 | [2020/48] | French: | EXPRESSION RÉGULÉE DE L'IL12 PAR LE RÉCEPTEUR SYNNOTCH | [2020/48] | Entry into regional phase | 18.08.2020 | Translation filed | 18.08.2020 | National basic fee paid | 18.08.2020 | Search fee paid | 18.08.2020 | Designation fee(s) paid | 18.08.2020 | Examination fee paid | Examination procedure | 18.08.2020 | Examination requested [2020/48] | 09.06.2022 | Amendment by applicant (claims and/or description) | 01.08.2023 | Application deemed to be withdrawn, date of legal effect [2023/52] | 23.08.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2023/52] | Fees paid | Renewal fee | 18.08.2020 | Renewal fee patent year 03 | 25.01.2022 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 31.01.2023 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XAI]WO2016138034 (UNIV CALIFORNIA [US]) [X] 1-7,10-12 * paragraph [0190] * * paragraph [0408] - paragraph [0409] * * paragraph [0423] - paragraph [0426] * * paragraph [0481] * * paragraph [0624] * [A] 8,9 [I] 13-20; | [XAI] - ROYBAL KOLE T ET AL, "Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors", CELL, ELSEVIER, AMSTERDAM NL, (20160929), vol. 167, no. 2, doi:10.1016/J.CELL.2016.09.011, ISSN 0092-8674, page 419, XP029761104 [X] 1-7,10-12 * page 420; figure 1 * * page 422; figure 2 * * page 429, column r, paragraph 3 * * page 430; figure 7 * [A] 8,9 [I] 13-20 DOI: http://dx.doi.org/10.1016/j.cell.2016.09.011 | [I] - ROYBAL KOLE T ET AL, "Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits", CELL, ELSEVIER, AMSTERDAM NL, (20160128), vol. 164, no. 4, doi:10.1016/J.CELL.2016.01.011, ISSN 0092-8674, pages 770 - 779, XP029416808 [I] 13-20 * abstract * * page 771; figure 1 * * page 774; figure 3 * * page 775; figure 4 * DOI: http://dx.doi.org/10.1016/j.cell.2016.01.011 | [T] - LUO HONG ET AL, "Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells", FRONTIERS IN ONCOLOGY, CH, (20191219), vol. 9, doi:10.3389/fonc.2019.01448, ISSN 2234-943X, XP055848481 [T] 1-20 * the whole document * DOI: http://dx.doi.org/10.3389/fonc.2019.01448 | International search | [A]US2004058443 (ARTAVANIS-TSAKONAS SPYRIDON [US], et al) [A] 1-35; | [A]WO2014055668 (SLOAN KETTERING INST CANCER [US]) [A] 1-35; | [X]US2017233474 (LIM WENDELL A [US], et al) [X] 1-35; | [X]CN107475275 (UNIV SHENZHEN) [X] 1-35; | [A] - HU Y., "Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy", ACTA PHARMACOLOGICA SINICA, (20170907), vol. 39, no. 2, pages 167 - 176, XP055625054 [A] 1-35 DOI: http://dx.doi.org/10.1038/aps.2017.125 | [A] - WU Siwei; AO Xiang; GUO Wei; XING Wei; AN Tianchen; AO Luoquan; HU Xueting; LI Zhan; XU Xiang, "Construction of GPC3-CAR-T cell targeting hepatocellular carcinoma and identification of its function", Chinese Journal of Cancer Biotherapy, (20171231), vol. 24, no. 7, doi:10.3872/j.issn.1007-385x.2017.07.009, pages 748 - 755, XP009522629 [A] 1-35 DOI: http://dx.doi.org/10.3872/j.issn.1007-385x.2017.07.009 | by applicant | US9834608 | CN20181053219 |